Your session is about to expire
← Back to Search
Trametinib + Docetaxel for Non-Small Cell Lung Cancer
Study Summary
This trial is testing how well trametinib and docetaxel work to treat patients with stage IV KRAS mutation positive non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 206 Patients • NCT02034110Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've had radiation that didn't affect more than 25% of my bone marrow and have recovered from its side effects.I am not taking any herbal supplements.Your hemoglobin level is at least 9 grams/dl, and this was checked within the last 28 days before joining the study.I haven't taken any cancer treatment or experimental drugs in the last 14 days and have recovered from side effects.Your blood platelet count is at least 100,000 per microliter, and this result was confirmed within the last 28 days before enrolling in the study.I can take care of myself and am up and about more than 50% of my waking hours.I don't have active brain cancer or symptoms after treatment for it.I have never had interstitial lung disease or pneumonitis.I do not have ongoing or untreated eye retina problems.I haven't taken any cancer drugs or been in a trial for 2 weeks and have recovered from side effects.My lung cancer is stage IV or recurrent with a confirmed KRAS mutation.My cancer can be seen on scans taken within the last 28 days.I don't have active brain cancer or symptoms after treatment for brain metastases.My lung cancer has worsened after 1-2 treatments, including one with platinum.I have not been treated with docetaxel or drugs targeting specific cancer pathways.I have recovered from side effects of my previous treatment, except for hair loss.My kidney function, measured by creatinine levels or clearance, is within the required range.I can take pills and don't have major GI issues affecting absorption.I don't have serious heart or stroke issues in the past 6 months.My heart's electrical activity is normal, and if I have atrial fibrillation, it's controlled or mild.My heart's pumping ability is within the normal range.I am not allergic to trametinib, its related drugs, or any agents used in the study.I do not have active hepatitis B or C, and I am not HIV positive.I have no cancer history except for certain skin cancers, early-stage cancers in remission, or cancers I've been free from for 3 years.I am not pregnant or nursing and will use effective birth control during the study.My white blood cell count is healthy.I have not been treated with anti-PD-1 or anti-PDL1 therapies.I have not been treated with anti-PD-1 or anti-PDL1 therapies.I haven't had major surgery in the last 28 days and have recovered from any past surgeries.My liver function tests are within the required range.My bilirubin levels are within normal range as tested in the last 28 days.
- Group 1: Treatment (trametinib, docetaxel)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How large is this study in terms of active participants?
"Unfortunately, this particular trial is not actively recruiting patients at the moment. However, there are nearly 1400 other cancer studies and 431 Trametinib trials that are presently looking for participants."
Are there still opportunities available to join this research project?
"The clinical trial referenced is not recruiting patients at this time. Based on the information found on clinicaltrials.gov, which was last updated on October 18th 2022, the study is no longer looking for candidates. There are, however, 1830 other trials that are recruiting patients as we speak."
What are some of the most popular off-label uses for Trametinib?
"Trametinib can be used to target the brca1 gene, neoplasm metastasis, and metastatic bladder cancer."
Has Trametinib been federally sanctioned for use?
"Trametinib's safety is estimated to be a 2. In other words, while there is some evidence that the drug is safe, there is no data supporting whether or not it is effective."
Are there other ongoing investigations involving Trametinib?
"As of now, 431 clinical trials investigating Trametinib are ongoing with 138 of them being Phase 3 studies. The majority of these research projects are based in Fuzhou, Fujian; however, there are 28190 total locations running trials for Trametinib."
In how many different places is this trial being run today?
"There are over 100 enrolling sites for this trial, including Providence Saint Mary Regional Cancer Center in Walla Walla, Washington, OptumCare Cancer Care at MountainView in Las Vegas, Nevada, and Saint Joseph Medical Center in Bloomington, Illinois."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger